Trials / Unknown
UnknownNCT02597387
Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs
A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with diffuse large B-cell lymphoma and lymphoma peripheral T cell.
Detailed description
A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas with dose of 20 mg/m2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitoxantrone HCL Liposome Injection |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2018-09-01
- Completion
- 2018-10-01
- First posted
- 2015-11-05
- Last updated
- 2018-08-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02597387. Inclusion in this directory is not an endorsement.